Ipratropium vs Oxitropium bromide (Ba253BINEB)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Ipratropium
Marketed by Boehringer Ingelheim
NCT06074185 · Phase 2 · completed
The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.
No aligned efficacy figure on record for this race.
Oxitropium bromide (Ba253BINEB)
Developed by Boehringer Ingelheim
NCT02182661 · Phase 3 · completed
The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ipratropium | Oxitropium bromide (Ba253BINEB) |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Not posted · NCT02182661 |
| Trough FEV1, change | —Not reported | —Not posted · NCT02182661 |
| ACQ-5, change | —Not reported | —Not posted · NCT02182661 |
| OCS dose reduction | —Not reported | —Not posted · NCT02182661 |
Severe exacerbations, annualised rate
- Ipratropium
- —Not reported
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
Trough FEV1, change
- Ipratropium
- —Not reported
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
ACQ-5, change
- Ipratropium
- —Not reported
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
OCS dose reduction
- Ipratropium
- —Not reported
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Oxitropium bromide (Ba253BINEB): no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ipratropium: 3 of 4 rows · Oxitropium bromide (Ba253BINEB): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ipratropium |
|---|---|
| Dropout rate | —a NCT06074185 · Phase 2 · combination show 4 more results0% NCT04617015 · Phase 1 · registry result, not featured evidence 0%Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 5.6%Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0% NCT00583778 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT06074185 · Phase 2 · combination show 4 more results— NCT04617015 · Phase 1 · registry result, not featured evidence —Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence —Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence — NCT00583778 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 0%a NCT06074185 · Phase 2 · combination show 4 more results0% NCT04617015 · Phase 1 · registry result, not featured evidence 0%Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0%Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0% NCT00583778 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | a upper respiratory infection 13.3% dyspnea 6.7% right foot fracture 6.7% NCT00521222 · Phase na · registry result, not featured evidence show 1 more resultdyspnea 11.8% cough 5.9% pneumonia 5.9% NCT00521222 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ipratropium
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ipratropium's landscape · Oxitropium bromide (Ba253BINEB)'s landscape